ESMO Open最新文献

{"title":"Response to Letter to the Editor Re: Impact of the Prosigna assay on neoadjuvant treatment decision making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study","authors":"C. Corti , S.M. Tolaney","doi":"10.1016/j.esmoop.2025.105861","DOIUrl":"10.1016/j.esmoop.2025.105861","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 11","pages":"Article 105861"},"PeriodicalIF":8.3,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145270471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial☆","authors":"M.V. Dieci ,&nbsp;G. Bisagni ,&nbsp;S. Bartolini ,&nbsp;L. Cavanna ,&nbsp;A. Musolino ,&nbsp;F. Giotta ,&nbsp;A. Rimanti ,&nbsp;O. Garrone ,&nbsp;E. Bertone ,&nbsp;K. Cagossi ,&nbsp;S. Sarti ,&nbsp;A. Ferro ,&nbsp;F. Piacentini ,&nbsp;E. Orvieto ,&nbsp;M. Sanders ,&nbsp;F. Miglietta ,&nbsp;S. Balduzzi ,&nbsp;R. D’Amico ,&nbsp;P. Conte ,&nbsp;V. Guarneri","doi":"10.1016/j.esmoop.2025.105832","DOIUrl":"10.1016/j.esmoop.2025.105832","url":null,"abstract":"<div><h3>Background</h3><div>We demonstrated the prognostic role of tumor-infiltrating lymphocytes (TILs) in patients with early human epidermal growth factor receptor 2 (HER2)-positive breast cancer (eBC) enrolled in the ShortHER trial. Here, we analyze how body mass index (BMI) modulates the prognostic role of TILs.</div></div><div><h3>Patients and methods</h3><div>The ShortHER study randomized 1253 patients with HER2-positive eBC to 9 weeks versus 1 year of adjuvant trastuzumab + chemotherapy. We assessed BMI at diagnosis (available for <em>n</em> = 1213, <em>n</em> = 34 underweight were excluded). Survival endpoints were disease-free survival (DFS), recurrence-free survival (RFS), distant DFS (DDFS) and overall survival (OS). We calculated the cumulative incidence of first event types by competing risk analysis.</div></div><div><h3>Results</h3><div>A total of 583 (48%) patients were lean, 360 (29.7%) overweight and 236 (19.5%) obese. Lean patients versus those with overweight or obesity had similar DFS, RFS, DDFS and OS. Within the TIL + BMI cohort (<em>n</em> = 819), TILs (5% increase) were independently associated with DFS (<em>P</em> = 0.003), RFS (<em>P</em> = 0.001) and DDFS (<em>P</em> = 0.018) in lean patients. In patients with overweight or obesity, TILs were independently associated only with DDFS (<em>P</em> = 0.044). In lean patients, TILs ≥20% were associated with improved DFS (<em>P</em> = 0.007), RFS (<em>P</em> = 0.002) and DDFS (<em>P</em> = 0.027) compared with TILs &lt;20%. In patients with overweight or obesity, DFS, RFS, DDFS and OS did not significantly differ between TILs ≥20% and TILs &lt;20%. In lean patients, there was a higher cumulative incidence of locoregional relapse (<em>P</em> = 0.001) and distant relapse (<em>P</em> = 0.07) in patients with TILs &lt;20% versus TILs ≥20%. In patients with overweight or obesity, there was a higher cumulative incidence of distant relapse (<em>P</em> = 0.005) in patients with TILs &lt;20% versus TILs ≥20%.</div></div><div><h3>Conclusions</h3><div>We suggest that BMI may impair the local, but not distant, protective effect of TILs in patients with overweight or obesity with HER2-positive eBC treated with adjuvant chemotherapy + trastuzumab.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 11","pages":"Article 105832"},"PeriodicalIF":8.3,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145270470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)","authors":"T. Masuishi ,&nbsp;H. Taniguchi ,&nbsp;D. Kotani ,&nbsp;H. Bando ,&nbsp;Y. Komatsu ,&nbsp;E. Shinozaki ,&nbsp;Y. Sunakawa ,&nbsp;T. Satoh ,&nbsp;T. Nishina ,&nbsp;T. Esaki ,&nbsp;M. Wakabayashi ,&nbsp;S. Nomura ,&nbsp;K. Takahashi ,&nbsp;H. Ono ,&nbsp;N. Hirano ,&nbsp;N. Fujishiro ,&nbsp;N. Fuse ,&nbsp;A. Sato ,&nbsp;Y. Sakamoto ,&nbsp;N. Kuramoto ,&nbsp;T. Yoshino","doi":"10.1016/j.esmoop.2025.105839","DOIUrl":"10.1016/j.esmoop.2025.105839","url":null,"abstract":"<div><h3>Background</h3><div>Based on the reported antitumor effects of microtubule inhibitors in xenograft models of <em>BRAF</em> V600E mutant colorectal cancer, this multicenter phase II study aimed to evaluate the efficacy and safety of eribulin in patients with <em>BRAF</em> V600E mutant metastatic colorectal cancer (mCRC).</div></div><div><h3>Patients and methods</h3><div>Patients with <em>BRAF</em> V600E mutant mCRC who received at least one prior regimen were administered intravenous eribulin. The primary endpoint was the objective response rate (ORR). Biomarker analyses were carried out using tumor and serial blood samples. Patients with reduced tumor size and/or progression-free survival (PFS) of &gt;6 months were classified into the good response group, and the remaining patients were classified into the poor response group.</div></div><div><h3>Results</h3><div>Among the 27 patients enrolled, the ORR was 0% (95% confidence interval 0.0% to 12.8%), the disease control rate was 41%, the median PFS was 1.4 months, and the median survival time was 5.3 months (median follow-up, 5.3 months). Of 26 patients for whom tumors for RNA sequencing were available, all four patients in the good response group had the <em>BRAF</em> mutant (BM)2 subtype on gene expression analysis of BM subtype, whereas 22 patients in the poor response group had the BM1 (<em>n</em> = 8) or BM2 (<em>n</em> = 14) subtypes (<em>P</em> = 0.07). The proportion of patients with decreasing <em>BRAF</em> V600E relative clonality at the start of the second cycle was 75% and 11% in the good response and poor response groups, respectively (<em>P</em> = 0.02). Grade 3 and 4 adverse events included neutropenia (63%) and febrile neutropenia (22%).</div></div><div><h3>Conclusions</h3><div>This phase II study of eribulin for patients with <em>BRAF</em> V600E mutant mCRC did not meet the primary endpoint. Although BM2 on gene expression analysis of BM subtype may be a predictive marker of eribulin efficacy, further studies are required to validate this hypothesis.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 11","pages":"Article 105839"},"PeriodicalIF":8.3,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145248010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing SERENA6 in the clinic in the UAE: critical thinking of a community oncologist","authors":"S. Dawood","doi":"10.1016/j.esmoop.2025.105849","DOIUrl":"10.1016/j.esmoop.2025.105849","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 11","pages":"Article 105849"},"PeriodicalIF":8.3,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145248009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial","authors":"E. Seguí ,&nbsp;F. Brasó-Maristany ,&nbsp;T. Pascual ,&nbsp;E. Sanfeliu ,&nbsp;I. Victoria ,&nbsp;C. Saura ,&nbsp;C. Hierro ,&nbsp;A. López-González ,&nbsp;Y. Izarzugaza ,&nbsp;E. Ciruelos ,&nbsp;J. Gavilá ,&nbsp;F. Racca ,&nbsp;J.M. Cejalvo ,&nbsp;K. Amillano ,&nbsp;L. Paz-Ares ,&nbsp;M. Juan ,&nbsp;E. Felip ,&nbsp;E. Garralda ,&nbsp;B. González ,&nbsp;A. Arance ,&nbsp;J. Tabernero","doi":"10.1016/j.esmoop.2025.105838","DOIUrl":"10.1016/j.esmoop.2025.105838","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitors (ICIs) have transformed the treatment of solid tumors, yet responses vary across cancer types, highlighting the need for reliable pan-cancer biomarkers. Prior retrospective studies identified <em>PD1</em> mRNA as a promising predictor of anti-PD1 response, but prospective validation was lacking.</div></div><div><h3>Patients and methods</h3><div>The SOLTI-1904 ACROPOLI trial was a non-randomized, open-label, multicenter phase II study designed to evaluate the efficacy of anti-PD1 monotherapy in patients with advanced solid tumors and high <em>PD1</em> mRNA expression (cohort 1). An exploratory cohort also enrolled <em>PD1</em>-low tumors from cancer types with known ICI sensitivity (cohort 2). Between April 2021 and March 2022, 1003 patients across 33 cancer types were prescreened; 10.6% were classified as <em>PD1</em>-high. A total of 56 <em>PD1</em>-high and 15 <em>PD1</em>-low cases were enrolled to receive spartalizumab (400 mg intravenously every 4 weeks). The primary endpoint was objective response rate (ORR) in <em>PD1</em>-high tumors. Cohorts 1 and 2 were closed early due to discontinuation of spartalizumab development, before reaching full accrual.</div></div><div><h3>Results</h3><div>In the <em>PD1-</em>cohort, which included heavily pretreated tumors (median two prior lines) across 19 histologies, the ORR was 17.9% (95% confidence interval 7.8% to 27.9%). Among patients with tissue samples collected within 12 months of treatment, the ORR increased to 33.3%. The clinical benefit rate (partial response or stable disease ≥24 weeks) was 30.4%. Responses occurred in cancers typically resistant to ICIs, including pancreatic and microsatellite-stable colorectal cancers. No new safety signals were identified. Programmed death-ligand 1 expression by immunohistochemistry was significantly associated with response, whereas exploratory analyses identified additional potential biomarkers, including B cell gene signatures and tumor proliferation markers.</div></div><div><h3>Conclusions</h3><div><em>PD1</em> mRNA may help identify immunogenic tumors across cancer types. However, the trial’s early closure and exploratory nature warrant further validation. A composite biomarker strategy integrating immune and tumor-intrinsic features may improve patient selection for ICIs.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 10","pages":"Article 105838"},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding first-line treatment patterns and survival outcomes across sociodemographic groups of women with metastatic triple-negative breast cancer in the United States: a real-world study","authors":"S.M. Tolaney ,&nbsp;L. Spring ,&nbsp;Y.G. Abdou ,&nbsp;M.K. Rehnquist ,&nbsp;C. Hogea ,&nbsp;A. Estrin ,&nbsp;N. Sjekloca ,&nbsp;C. Lai ,&nbsp;K. Kalinsky","doi":"10.1016/j.esmoop.2025.105841","DOIUrl":"10.1016/j.esmoop.2025.105841","url":null,"abstract":"<div><h3>Background</h3><div>Triple-negative breast cancer (TNBC) has poor prognosis, and disproportionately affects young black women and <em>BRCA1/2</em> mutation carriers. We describe sociodemographic differences in real-world treatment patterns and survival outcomes in women with metastatic TNBC (mTNBC) in the United States.</div></div><div><h3>Patients and methods</h3><div>This retrospective, real-world cohort study used de-identified data from patients in the Flatiron Health database diagnosed with mTNBC who received first-line (1L) treatment between January 2018 and July 2022. Patient characteristics, treatment patterns, real-world overall survival (rwOS), and time to next treatment or death (TTNTD) were determined in the overall population and by race, socioeconomic status (SES) index, United States region, and treatment setting.</div></div><div><h3>Results</h3><div>Of 1555 women diagnosed with mTNBC, 930 women received 1L treatment and were included. Overall, 55% of women were white, 43% were from the South, and 83% were treated at community centers. 1L treatment patterns were similar across all subgroups. Overall, 69% of patients received chemotherapy only, 28% received programmed death-(ligand) protein 1 [PD-(L)1] inhibitors, and 2% poly (ADP-ribose) polymerase inhibitors (PARPi). Documented testing rate for PD-L1 expression was 80% and highest in the Northeast (91%), Midwest (86%), and community centers (82%). Among 559 women with documented PD-L1 expression, 82% were treated with PD-(L)1 inhibitors in any metastatic line. Documented testing rate for <em>BRCA1/2</em> mutation was 55% and highest in the West (63%) and in academic practices (59%). Among 508 women with documented <em>BRCA1/2</em> mutations, 56% were treated with PARPis in any metastatic line; no black woman received a 1L PARPi regardless of mutation status. There were no statistically significant differences in survival outcomes across sociodemographic groups, and, overall, patients had poor survival (rwOS: 12.0 months; TTNTD: 4.2 months).</div></div><div><h3>Conclusions</h3><div>This study demonstrated generally similar treatment patterns and poor survival outcomes across sociodemographic groups, highlighting an unmet need for more efficacious treatments for all women with mTNBC.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 10","pages":"Article 105841"},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial","authors":"Y.Y. Janjigian ,&nbsp;A. Kawazoe ,&nbsp;J. Xu ,&nbsp;S. Lonardi ,&nbsp;J.-P. Metges ,&nbsp;L.S. Wyrwicz ,&nbsp;L. Shen ,&nbsp;Y. Ostapenko ,&nbsp;M. Bilici ,&nbsp;M.A. Lowery ,&nbsp;A. Valderrama ,&nbsp;Y. Guan ,&nbsp;K. Li ,&nbsp;C.-S. Shih ,&nbsp;S.Y. Rha","doi":"10.1016/j.esmoop.2025.105542","DOIUrl":"10.1016/j.esmoop.2025.105542","url":null,"abstract":"<div><h3>Background</h3><div>In the primary analysis of the randomized phase III KEYNOTE-811 trial (NCT03615326), pembrolizumab plus trastuzumab and chemotherapy improved progression-free survival and overall survival versus placebo plus trastuzumab and chemotherapy in participants with previously untreated human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer.</div></div><div><h3>Patients and methods</h3><div>Overall, 698 participants were randomly assigned (1 : 1) to pembrolizumab 200 mg or placebo every 3 weeks, both with trastuzumab and chemotherapy. We report prespecified exploratory patient-reported outcomes (PROs), including change from baseline, time to deterioration (TTD), and overall improvement/stability rate assessed in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) scales/items, EORTC Quality of Life Questionnaire-Stomach 22 pain scale, and EuroQoL 5-dimension 5-level questionnaire visual analog scale.</div></div><div><h3>Results</h3><div>The PRO population comprised 685 participants. At baseline, the rates of compliance and completion for all PRO questionnaires and for both treatment groups were &gt;92%; at week 24, the rates were &gt;80% and &gt;55%, respectively. No between-group differences were observed from baseline to week 24 for the QLQ-C30 global health status/quality of life (GHS/QoL) scale [least squares mean (LSM) difference −1.16; 95% confidence interval (CI) −4.23 to 1.91] and EQ VAS (LSM difference, −0.69; 95% CI −3.06 to 1.68). Median TTD was not reached. A similar proportion of participants in each treatment group had improved and/or stable scores in the QLQ-C30 GHS/QoL scale (pembrolizumab group 71.9%; placebo group 71.5%). Findings were similar for all other prespecified scales/items.</div></div><div><h3>Conclusions</h3><div>While improving clinical outcomes, the addition of pembrolizumab to trastuzumab and chemotherapy did not negatively impact health-related quality of life during treatment, supporting the use of pembrolizumab plus trastuzumab and chemotherapy for first-line treatment of HER2-positive advanced gastric cancer.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 10","pages":"Article 105542"},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cyclin-dependent kinase 4/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study)","authors":"L.F.C. de Almeida ,&nbsp;L.F. Leite ,&nbsp;V.O.C. Filho ,&nbsp;M.M. Noronha ,&nbsp;A.P. Cappellaro ,&nbsp;M. Gouveia ,&nbsp;J.L. da Silva ,&nbsp;B. Ernst ,&nbsp;A.C. de Melo ,&nbsp;P. Tarantino ,&nbsp;F. Batalini","doi":"10.1016/j.esmoop.2025.105808","DOIUrl":"10.1016/j.esmoop.2025.105808","url":null,"abstract":"<div><h3>Background</h3><div>Adding cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) to endocrine therapy (ET) is considered the first-line treatment of advanced HR-positive/HER2-negative breast cancer. However, with the recent approval of several additional targeted agents, the optimal treatment sequencing remains uncertain, and it is unclear whether the benefits of CDK4/6i extend beyond progression on first-line therapy.</div></div><div><h3>Materials and methods</h3><div>We conducted a systematic review and meta-analysis to evaluate the efficacy of CDK4/6i in the second-line setting after progression on CDK4/6i in the first line, with a particular focus on patients who had either <em>PIK3CA</em> or <em>ESR1</em> mutation. We included randomized clinical trials (RCTs) comparing CDK4/6i combined with ET to ET alone in patients who experienced tumor progression on CDK4/6i treatment in the first-line setting. The results were pooled using a random-effects model with 95% confidence interval (CI).</div></div><div><h3>Results</h3><div>Five RCTs encompassing 1184 patients were included. Overall, CDK4/6i plus ET significantly improved progression-free survival (PFS) versus ET alone, yielding a hazard ratio of 0.73 (95% CI 0.56-0.94, <em>P</em> &lt; 0.05), with a more prominent benefit in patients who switched the CDK4/6i (hazard ratio 0.61, 95% CI 0.48-0.77, <em>P</em> &lt; 0.05). The benefit was consistent in patients with somatic <em>PIK3CA</em> mutations (hazard ratio 0.71, 95% CI 0.52-0.98, <em>P</em> &lt; 0.05), and <em>ESR1</em> mutations (hazard ratio 0.66, 95% CI 0.49-0.89, <em>P</em> &lt; 0.05). The toxicity profile was compatible with the known side effects from CDK4/6i.</div></div><div><h3>Conclusions</h3><div>Our results support the strategy of switching the CDK4/6i in the second-line setting and demonstrate persistent benefit even in patients with <em>PIK3CA</em> or <em>ESR1</em> mutations.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 10","pages":"Article 105808"},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter re: Improving chemotherapy-induced peripheral neuropathy in cancer patients using a combined qigong and self-administered acupressure intervention: a randomized controlled trial","authors":"D.S.T. Cheung","doi":"10.1016/j.esmoop.2025.105836","DOIUrl":"10.1016/j.esmoop.2025.105836","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 10","pages":"Article 105836"},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145227416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimum standards of specialist adolescent and young adult (AYA) cancer care units: recommendations and implementation roadmap","authors":"U. Košir ,&nbsp;A. Totovina ,&nbsp;D. Stark ,&nbsp;A. Ferrari ,&nbsp;J. de Munter ,&nbsp;W.T.A. van der Graaf ,&nbsp;E. Manten-Horst ,&nbsp;K. Rizvi","doi":"10.1016/j.esmoop.2025.105829","DOIUrl":"10.1016/j.esmoop.2025.105829","url":null,"abstract":"<div><div>In 2022, according to the Global Cancer Observatory, &gt;115 000 adolescents and young adults (AYAs; aged 15-39 years) were diagnosed with cancer across Europe. Despite their unique biological and psychosocial needs, AYAs face disparity of access to specialised oncology services, particularly outside major urban centres in the east and south of Europe. Addressing these inequalities is essential to ensuring comprehensive and equitable cancer care. As part of EU4Health, the European Union Network of Youth Cancer Survivors (EU-CAYAS-NET) consortium was established to advance Europe’s Beating Cancer Plan. The project aimed to develop—with patient organisations at the helm—evidence-based recommendations to standardise and improve care across Europe, ultimately enhancing outcomes and quality of life for all young people.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 10","pages":"Article 105829"},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}